Peregrine: Continuing to Accumulate on Any Dips

PPHM: Shares of Peregrine traded with some strength on Monday after the company opened trading after having have conducted a 1:5 reverse split.
The company also took the opportunity on Monday morning to announce that former Genentech Senior Executive Dr. Robert Garnick has joined Peregrine as the Head of Regulatory Affairs.

I maintain that PPHM is full of future potential based on the bavituximab and Cotara pipeline, although those products have yet to hit Phase III.

I'll continue to accumulate on any dips.

Of note, the stock will continue trading as PPHMD until the end of the month.

Disclosure: VFC is long PPHM.

Comments

[jay brebner:]

very bullish sign after an RS.

Oct 20 10:11 AM

[DNAdivaSTL:]

Please advise on what Fidelity is calling a "merger?" When I was checking the staus on my portfolio, I noticed that the shares were not listed... upon further research, the merger explanation is all I can find?

Oct 29 05:17 PM

[nucs:]

VFC,

I am a big fan of Cotara. Another RIT with seemingly overwhelming efficacy data.(some instances of survival out 10 years in aggressive gbm- amazing stuff) I haven't bought any shares yet, as the balance sheet has been a big concern for me. I will probably look into the stock again. Are they on firm financial footing? When do you think they could start a pivotal trial for Cotara? Hopefully Zevalin can lead the push into more uptake in RIT, and then pave the way for some promising RIT like Cotara.

Nov 15 11:15 AM

[nucs:]

O.K. my mistake this is not RIT, but TNT. I will have to look into more to see how this gets into the core of the tumor. As I don't know its mechanism of action. It is not intravenously injected, and appears to be injected directly into the tumor.

Nov 15 12:03 PM

[nucs:]

O.K. so it appears this monoclonal antibody attaches itself to dieing tumors cells within the tumor itself. From what I can tell from the description of mechanism of action, there is no immune response thus not an RIT. It appears that all the killing activity is done by the radiation only, right? When I first looked into the company, I assumed RIT. I figured that all monoclonal antibodies created an immune response. Just a little confused is all.


On Nov 15 12:03 PM nucs wrote:

> O.K. my mistake this is not RIT, but TNT. I will have to look into
> more to see how this gets into the core of the tumor. As I don't
> know its mechanism of action. It is not intravenously injected,
> and appears to be injected directly into the tumor.

Nov 15 12:27 PM